A pharmacological surveillance study of the tolerability of policosanol in the elderly population

American Journal Geriatric Pharmacotherapy

Volumn 2, Issue 4, 2004, Pages 219-229

  Fernández, Salome ^a   Más, Rosa ^a   Gamez, Rafael ^a   Diaz, Arquímedes ^a   Fernández, Julio ^a   Orta, Santa Deibis ^a   Illnait, José ^a   Castaño, Gladys ^a   Mendoza, Sarahi ^a   Valdés, Francisco ^a   Alvarez, Estrella ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Adverse events; Cholesterol; Elderly; Policosanol; Postmarketing surveillance

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; POLICOSANOL;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; ATHEROSCLEROSIS; BRADYCARDIA; BRONCHITIS; CATARACT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL PRACTICE; COLON CANCER; CONTRACTURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CUBA; CYSTITIS; DEHYDRATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GASTRODUODENAL ULCER; GLAUCOMA; HEALTH CARE FACILITY; HEARING IMPAIRMENT; HEART ARREST; HEART INFARCTION; HEART MURMUR; HEART VENTRICLE ARRHYTHMIA; HEARTBURN; HEMORRHOID; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFLUENZA; KIDNEY CYST; LUNG CANCER; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MUSCLE CRAMP; PATIENT INFORMATION; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PERITONITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM DISEASE; RISK ASSESSMENT; STOMACH CANCER; TESTIS DISEASE; THORAX PAIN; VISUAL IMPAIRMENT;

AGED; ANTICHOLESTEREMIC AGENTS; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 20144374934     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2004.12.004     Document Type: Article

References (44)

1. Lipid Research Clinics Program The Lipid Research Clinics coronary primary prevention trial results. II. The relationship on reduction in the incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365-374
2. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383-1389
3. Sacks FM Pfeffer MA Moyé LA et al. for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001-1009
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349-1357
5. Shepherd S Cobbe SM Ford I et al. for the West of Scotland Coronary Prevention Study Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301-1307
6. Downs JR Clearfield M et al. for the Weiss S AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS JAMA 279 1998 1615-1622
7. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial Lancet 360 2002 7-22
8. Shepherd J Blauw GJ Murphy MB et al. on behalf of the PROSPER Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled study Lancet 360 2002 1623-1630
9. Manolio TA Pearson TA Wenger NK et al. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop Ann Epidemiol. 2 1992 161-176
10. Bilheimer DW Clinical considerations regarding treatment of hypercholesterolemia in the elderly Atherosclerosis 91 1991 (Suppl) S35-S57
11. Más R Policosanol Drugs Future 25 2000 569-586
12. Menéndez R Fernández I Del Rio A et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts Biol Res. 27 1994 199-203
13. Menéndez R Arruzazabala ML Más R et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet Brit J Nutr. 77 1996 923-932
14. Menéndez R Amor A Rodeiro I et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts Arch Med Res. 32 2001 8-12
15. Hernéndez F Illnait J Más R et al. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers Curr Ther Res Clin Exp 51 1992 568-575
16. Pons P Rodriguez M Robaina C et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment Int J Clin Pharmacol Res. 14 1994 27-33
17. Más R Castaño G Illnait J et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors Clin Pharmacol Ther. 65 1999 439-447
18. Castaño G Más R Fernández L et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia Gynecol Endocrinol 13 2000 1-9
19. Castaño G Más R Arruzazabala ML et al. Effects of policosanol, pravastation on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients Int Clin Pharm Res. 19 1999 105-116
20. Fernández JC Más R Castaño G et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women Clin Invest. 21 2001 103-113
21. Castaño G Más R Fernández JC et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk J Gerontol A. 56 2001 M186-M192
22. Más R Castaño G Fernández L et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease Clin Drug Invest. 21 2001 485-497
23. Castaño G Más R Fernández L et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolemia Drugs Aging 20 2002 153-163
24. Más R Castaño G Fernández J et al. Effects of policosanol on morbidity and mortality in older hypercholesterolemic patients J Am Coll Cardiol. 39 Suppl B 2002 429B Abstract
25. Torres O Agramonte AJ Illnait J et al. Treatment of hypercholesterolemia in NIDDM with policosanol Diabetes Care 18 1995 393-397
26. Crespo N Illnait J Más R et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus Int J Clin Pharmacol Res. 19 1999 117-127
27. Castaño G Fernández L Más R et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidemia and type 2 diabetes mellitus Clin Drug Invest. 23 2003 639-650
28. Arruzazabala ML Carbajal D Molina V et al. Effect of policosanol on cerebral ischemia in mongolian gerbils: Role of prostacyclin and thromboxane A2 Prostaglandins Leukot Essent Fatty Acids 49 1993 695-697
29. Arruzazabala ML Valdés S Más R et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers Pharmacol Res. 34 1996 181-185
30. Carbajal D Arruzazabala ML Valdés S Más R Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers Prostaglandins Leukot Essent Fatty Acids 58 1998 61-64
31. Arruzazabala ML Más R Molina V et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients Int J Tissue React 10 1998 119-124
32. Alemán C Más R Rodeiro I et al. Acute, subchronic and chronic toxicology of policosanol in rats Abstract of the 6th International Congress of Toxicology, Rome, Italy Toxicol Lett. 1992 (Suppl) 248
33. Mesa A del R Más R Noa M et al. Toxicity of policosanol in beagledogs: One year study Toxicol Lett. 73 1994 81-90
34. Alemán C Más R Hernandez C et al. A 12-month study of policosanol oral toxicity in Sprague-Dawley rats Toxicol Lett. 70 1994 77-87
35. Alemán CL Más R Noa M et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study Teratog Carcinog Mutagen. 14 1994 239-249
36. Rodríguez MD García H Teratogenic and reproductive studies of policosanol in the rat and rabbit Teratog Carcinog Mutagen 14 1994 107-113
37. Fernández L Más R Illnait J Fernández JC Policosanol: Results of a postmarketing surveillance control on 27 879 cases Curr Ther Res Clin Exp. 59 1998 717-722
38. Más R Rivas P Izquierdo JE et al. Pharmacoepidemiologic study of policosanol Curr Ther Res Clin Exp. 60 1999 458-467
39. Naranjo CA Busto U Sellers EM et al. A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther. 30 1981 239-245
40. Baker SK Tarnopolsky MA Statin myopathies: Pathophysiologic and clinical perspectives Clin Invest Med. 24 2001 258-272
41. Gaist D García A Huerta C et al. Lipid-lowering drugs and risk of myopathy: A population-based followup study Epidemiology 12 2001 565-569
42. Pasternak RC Smith SC Jr Bairey Merz CN et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567-572
43. Zardoya R Tula L Castaño G et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function Curr Ther Res Clin Exp. 57 1996 568-577
44. Snider SR Octacosanol in parkinsonism [letter] Ann Neurol. 16 1984 723